There may be more to mesothelioma than mesothelin

Mesothelin has been used as a biomarker for mesothelioma, including in marketed tests such as Fujirebio Diagnostics' Mesomark test, but a study published in the Journal of Clinical Oncology has suggested that the search for biomarkers for this rare cancer is not over. Mesothelioma is a type of cancer seen in people exposed to asbestos, and the most common form is plural mesothelioma, where the cancer develops on the outer side of the lungs and the inside of the chest wall. In the study, the researchers looked at 16 studies measuring serum mesothelin using the Mesomark diagnostic test. They found that while increased levels of mesothelin should suggest further investigation, mesothelin as a biomarker is not sensitive enough to use alone for early diagnosis. While this does not suggest that the Mesomark test is not accurate or useful, it does imply that more research is needed to find other biomarkers, perhaps to use in combination with mesothelin. Biomarkers currently being researched, according to the blog Surviving Mesothelioma, include osteopontin, angiopoietin-1, serum thioredoxin-1, calretinin, and the antibodies MMP1 and MMP9. Abstract | Blog post

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.